Incannex Healthcare (IXHL) vs Zhengye Biotechnology (ZYBT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Zhengye Biotechnology (ZYBT) has outperformed Incannex Healthcare (IXHL) over the past year, losing 36.4% versus a loss of 75.4%. Zhengye Biotechnology is the larger company by market cap ($82.0 million vs $38.9 million), about 2.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IXHL | ZYBT |
|---|---|---|
| Share price | $3.10 | $1.73 |
| Market cap | $38.89M | $81.99M |
| 1-day change | -3.13% | +50.45% |
| YTD return | -71.14% | +50.43% |
| 1-year return | -75.40% | -36.40% |
| EPS (TTM) | $-1.61 | $-0.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.91 | $8.01 |
| 52-week low | $2.49 | $0.616 |
| Distance from 52-week high | -79.21% | -78.40% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +502.58% | — |
| Average volume | 93.98K | 5.19M |
| Shares outstanding | 12.54M | 47.39M |
| Employees | 12 | 269 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Zhengye Biotechnology is about 2.1 times larger than Incannex Healthcare by market value ($81.99M vs $38.89M).
- ZYBT has outperformed IXHL by 39.0 percentage points over the past year.
About Incannex Healthcare
IXHL stock →Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
About Zhengye Biotechnology
ZYBT stock →Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine.
Health Care · Biotechnology: Pharmaceutical Preparations · 269 employees
IXHL vs ZYBT FAQ
Which is bigger, Incannex Healthcare or Zhengye Biotechnology?
Zhengye Biotechnology (ZYBT) is larger, with a market capitalization of $81.99M compared with $38.89M for Incannex Healthcare (IXHL).
Which stock has performed better over the past year, IXHL or ZYBT?
ZYBT returned -36.40% over the past 12 months, compared with -75.40% for IXHL (price return, excluding dividends). Past performance does not predict future results.
Are Incannex Healthcare and Zhengye Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.